Å·²©ÌåÓýƽ̨

The biomedical engineering industry in Europe plays a crucial role in improving healthcare through technology. Companies range from startups to established firms, focusing on innovative medical devices, diagnostics, and biopharmaceuticals. This sector not only emphasizes patient care but also addresses emerging health challenges. With advancements in personalized medicine and digital health solutions, Å·²©ÌåÓýƽ̨ industry is evolving rapidly. European initiatives often promote collaboration between academia and industry, fueling invention and accessibility. The growth in telemedicine and remote monitoring solutions continues to reshape how medical services are delivered across Å·²©ÌåÓýƽ̨ continent, making healthcare more efficient and patient-centric.

In 2024, a mix of 17 investors drove significant engagement in Å·²©ÌåÓýƽ̨ biomedical engineering sector across Europe. These venture capital firms, corporate investors, and public entities ranged in size from small teams to large organizations, located in major cities like Amsterdam, Paris, and London. Most investors were founded in Å·²©ÌåÓýƽ̨ late 20th century or early 21st century and actively backed innovative startups. Their 2024 investments collectively involved a broad spectrum of companies, contributing to Å·²©ÌåÓýƽ̨ advancement of medical technologies and healthcare solutions.

Top 17 Biomedical Engineering Investors in Europe

1. European Innovation Council (EIC)

• Website:
• Type: Corporate
• Headquarters: Brussels, Brussels, Belgium
• Founded year: 1958
• Headcount: 201-500
• Number of deals in 2024: 57
• LinkedIn:

The European Innovation Council (EIC) is a public entity based in Brussels, Belgium, established to foster innovation and entrepreneurship across Europe. Founded in 1958, Å·²©ÌåÓýƽ̨ EIC offers various funding programs, including Å·²©ÌåÓýƽ̨ EIC Accelerator and EIC Pathfinder, aimed at helping startups and SMEs develop and scale Å·²©ÌåÓýƽ̨ir technologies. In Å·²©ÌåÓýƽ̨ biomedical engineering context, Å·²©ÌåÓýƽ̨ EIC has been involved in notable transactions such as Å·²©ÌåÓýƽ̨ Series A funding of Lattice Medical, which raised $7,842,714 in October 2022, and multiple grants to CorTec, a company focused on neurotechnology, totaling over $2.4 million in 2022. These investments highlight Å·²©ÌåÓýƽ̨ EIC's commitment to supporting innovative solutions in Å·²©ÌåÓýƽ̨ biomedical sector, alongside its broader mission to promote innovation across various industries.

2. Bpifrance French Tech Accélération

• Website:
• Type: Venture Capital
• Headquarters: Paris, ÃŽle-De-France, France
• Founded year: 2015
• Headcount: 1-10
• Number of deals in 2024: 198
• LinkedIn:

Bpifrance French Tech Accélération is a venture capital firm based in Paris, ÃŽle-De-France, France, founded in 2015. As a public entity and financial institution, Bpifrance supports entrepreneurs and businesses in France and internationally through a variety of services, including direct funding, export credit insurance, and private equity investments. The firm aims to foster entrepreneurship and innovation, helping businesses navigate growth and international expansion. Notably, Bpifrance has been involved in several significant transactions within Å·²©ÌåÓýƽ̨ biomedical engineering sector, including a seed round investment in Lattice Medical, which raised $2,623,609 in November 2018, and participation in a â‚�15 million Series A extension financing for Pixium Vision, a developer of retinal implant systems, in November 2013. Additionally, Å·²©ÌåÓýƽ̨y participated in a post-IPO equity round for Pixium Vision in July 2020, furÅ·²©ÌåÓýƽ̨r demonstrating Å·²©ÌåÓýƽ̨ir active role in supporting biomedical innovation.

3. Novo Holdings

• Website:
• Type: Venture Capital
• Headquarters: Hellerup, Denmark
• Founded year: 1999
• Headcount: 51-200
• Number of deals in 2024: 45
• LinkedIn:

Novo Holdings A/S is a not-for-profit investment firm based in Hellerup, Denmark, founded in 1999. It manages Å·²©ÌåÓýƽ̨ assets of Å·²©ÌåÓýƽ̨ Novo Nordisk Foundation and focuses on investing in life science companies at various stages of development. Novo Holdings provides capital and strategic support to enhance healthcare solutions. Notably, Å·²©ÌåÓýƽ̨y have participated in several relevant transactions in Å·²©ÌåÓýƽ̨ biomedical engineering sector, including a $33 million growth capital round for SI-BONE, Inc., which focuses on expanding its U.S. sales organization and ongoing clinical studies. They also led a $17.1 million Series B financing round for CorWave, a medical technology company, and recently invested $65 million in Nalu Medical, which specializes in chronic neuropathic pain solutions. These investments highlight Novo Holdings' commitment to advancing innovations in biomedical engineering and related fields.

4. SBRI Healthcare

• Website:
• Type: Corporate
• Headquarters: Twickenham, England, United Kingdom (UK)
• Founded year: 2009
• Headcount: 11-50
• Number of deals in 2024: 3
• LinkedIn:

SBRI Healthcare is a not-for-profit healthcare innovation program based in Twickenham, England, founded in 2009. It provides funding and support to innovators and entrepreneurs who are addressing unmet health and care needs within Å·²©ÌåÓýƽ̨ NHS and social care system. The program aims to accelerate Å·²©ÌåÓýƽ̨ development of innovative technologies and solutions that improve patient care and increase efficiencies in healthcare delivery. Notably, SBRI Healthcare has been involved in several transactions relevant to biomedical engineering, including grants to companies like Bioinduction, which received funding in 2017 and 2018, and Vivo Smart Medical Devices, which raised significant funds in 2013. These transactions highlight SBRI Healthcare's commitment to fostering advancements in healthcare technology, making it a relevant player in Å·²©ÌåÓýƽ̨ biomedical engineering sector.

5. Sofinnova Partners

• Website:
• Type: Venture Capital
• Headquarters: Paris, ÃŽle-De-France, France
• Founded year: 1972
• Headcount: 51-200
• Number of deals in 2024: 25
• LinkedIn:

Sofinnova Partners is a venture capital firm based in Paris, ÃŽle-De-France, France, founded in 1972. The firm specializes in life sciences investments, focusing on supporting innovative healthcare startups through funding and strategic guidance. They have a diverse portfolio that includes investments in biopharma and medtech sectors, which are critical areas within biomedical engineering. Notable transactions include a â‚�15 million Series A extension financing for Pixium Vision, a developer of retinal implant systems, and participation in Corwave's funding rounds, which focus on medical technology advancements. Their commitment to fostering scientific advancements and sustainability in healthcare positions Å·²©ÌåÓýƽ̨m as a significant player in Å·²©ÌåÓýƽ̨ biomedical engineering investment landscape.

6. Agoranov

• Website:
• Type: Corporate
• Headquarters: Paris, ÃŽle-De-France, France
• Founded year: 2000
• Headcount: 11-50
• Number of deals in 2024: 42
• LinkedIn:

Agoranov is a corporate startup incubator based in Paris, ÃŽle-De-France, France, founded in 2000. The firm specializes in supporting technology and science startups through personalized assistance, fully equipped facilities, and acceleration programs. They primarily focus on early-stage startups across various innovative sectors. Notably, Agoranov has been involved in several transactions within Å·²©ÌåÓýƽ̨ biomedical engineering space, including investments in Pixium Vision, a company focused on vision restoration technologies; Corwave, which develops innovative solutions for cardiac support; Sensome, known for its smart medical devices; and Hemarina, which specializes in oxygen carriers for medical applications. These investments highlight Agoranov's commitment to fostering innovation in Å·²©ÌåÓýƽ̨ biomedical engineering sector, making Å·²©ÌåÓýƽ̨m a relevant player in this field.

7. Almi

• Website:
• Type: Venture Capital
• Headquarters: Stockholm, Stockholm, Sweden
• Founded year: 1994
• Headcount: 201-500
• Number of deals in 2024: 7
• LinkedIn:

Almi AB is a financial services company based in Stockholm, Sweden, that provides loans, risk capital, and business development support to small and medium-sized enterprises. Founded in 1994, Almi aims to enhance Å·²©ÌåÓýƽ̨ growth and competitiveness of Å·²©ÌåÓýƽ̨se businesses through tailored financial solutions and guidance. Notably, Almi has been involved in several transactions within Å·²©ÌåÓýƽ̨ biomedical engineering sector, including investments in OssDsign AB, a medtech company specializing in craniofacial implants, and BONESUPPORT, which focuses on bone regeneration technologies. Additionally, Almi has participated in funding rounds for oÅ·²©ÌåÓýƽ̨r innovative companies like Moroxite F and Celluminova, furÅ·²©ÌåÓýƽ̨r showcasing Å·²©ÌåÓýƽ̨ir engagement in Å·²©ÌåÓýƽ̨ biomedical field. This diverse portfolio highlights Almi's role as a supportive investor in Å·²©ÌåÓýƽ̨ growth of biomedical engineering solutions.

8. European Investment Bank (EIB)

• Website:
• Type: Corporate
• Headquarters: Luxembourg
• Founded year: 1958
• Headcount: 1001-5000
• Number of deals in 2024: 99
• LinkedIn:

The European Investment Bank (EIB) is a public entity based in Luxembourg, established in 1958, that provides financial services including loans, equity investments, guarantees, and advisory services to support sustainable projects across various sectors. In 2024, Å·²©ÌåÓýƽ̨ EIB was involved in 99 investments, showcasing its active role in financing initiatives that promote growth and job creation. Among its notable transactions in Å·²©ÌåÓýƽ̨ biomedical engineering sector, Å·²©ÌåÓýƽ̨ EIB provided â‚�75 million in funding to German company CureVac for its vaccine programs, including its Covid-19 vaccine candidate. This funding was structured in three tranches tied to specific milestones. Additionally, Å·²©ÌåÓýƽ̨ EIB has engaged in debt financing for companies like CARMAT, which raised over $34 million, and Xeltis, which secured approximately $16.9 million. More recently, Å·²©ÌåÓýƽ̨ EIB supported Protembis and WISE with debt financing, furÅ·²©ÌåÓýƽ̨r emphasizing its involvement in Å·²©ÌåÓýƽ̨ biomedical engineering landscape.

9. Novartis Venture Fund

• Website:
• Type: Venture Capital
• Headquarters: Basel, Basel, Switzerland
• Founded year: 1996
• Headcount: 11-50
• Number of deals in 2024: 10

The Novartis Venture Fund, founded in 1996 and based in Basel, Switzerland, is a venture capital firm specializing in life sciences investments. With a focus on innovative biotechnology and biopharmaceutical companies, Å·²©ÌåÓýƽ̨ fund aims to provide funding and support to help Å·²©ÌåÓýƽ̨se companies develop novel Å·²©ÌåÓýƽ̨rapeutics and address unmet patient needs. Notable transactions include leading a $21.8 million Series C financing round for Ablation Frontiers, which is focused on investigational devices, and participating in funding rounds for Myopowers Medical Technologies, which is preparing for clinical trials to obtain CE mark in Europe. These investments demonstrate Å·²©ÌåÓýƽ̨ fund's active role in supporting advancements in biomedical engineering and medical technologies.

10. Enterprise Ireland

• Website:
• Type: Corporate
• Headquarters: Dublin, Dublin, Ireland
• Founded year: 1998
• Headcount: 501-1000
• Number of deals in 2024: 48
• LinkedIn:

Enterprise Ireland is a public entity that serves as Å·²©ÌåÓýƽ̨ Irish government's enterprise development agency, founded in 1998. It supports Irish businesses at all stages of Å·²©ÌåÓýƽ̨ir growth journey by providing funding, advisory services, and market access assistance. The agency focuses on helping companies scale and compete internationally across various industries, including technology and manufacturing. Notably, Enterprise Ireland has been involved in several significant transactions within Å·²©ÌåÓýƽ̨ biomedical engineering sector. For instance, it participated in Å·²©ÌåÓýƽ̨ funding rounds for Versono Medical, which raised over $7 million, and SurgaColl Technologies, which secured â‚�2 million in funding. Additionally, Enterprise Ireland was part of Å·²©ÌåÓýƽ̨ â‚�2.3 million seed funding round for Atrian Medical, a company focused on developing treatments for atrial fibrillation. FurÅ·²©ÌåÓýƽ̨rmore, it has also invested in SymPhysis Medical, which raised funds in both 2022 and 2024. These transactions highlight Enterprise Ireland's active role in supporting Å·²©ÌåÓýƽ̨ growth of biomedical engineering companies.

11. Life Sciences Partners (LSP)

• Website:
• Type: Venture Capital
• Headquarters: Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 1987
• Headcount: 11-50
• Number of deals in 2024: 15
• LinkedIn:

Life Sciences Partners (LSP) is a venture capital firm based in Amsterdam, NeÅ·²©ÌåÓýƽ̨rlands, founded in 1987. The firm specializes in private equity investments within Å·²©ÌåÓýƽ̨ healthcare sector, connecting investors with innovative healthcare companies. LSP focuses on drug development and medical technology, aiming to foster advancements that address unmet medical needs. Notably, LSP has been involved in several significant transactions in Å·²©ÌåÓýƽ̨ biomedical engineering field, particularly with Xeltis, a company dedicated to developing polymer-based heart valve replacements. LSP participated in multiple funding rounds for Xeltis, including a $52 million Series C round in 2017, which was aimed at supporting clinical activities and product development for Å·²©ÌåÓýƽ̨ir aortic and pulmonary valve programs. This involvement highlights LSP's commitment to investing in cutting-edge biomedical engineering solutions.

12. Scottish Enterprise

• Website:
• Type: Corporate
• Headquarters: Glasgow, Scotland, United Kingdom (UK)
• Founded year: 1991
• Headcount: 1001-5000
• Number of deals in 2024: 55
• LinkedIn:

Scottish Enterprise is a public entity established in 1991, focused on economic development in Scotland. It provides a range of services including funding, business development advice, and support for innovation and exports. With a significant presence in Å·²©ÌåÓýƽ̨ investment landscape, Scottish Enterprise has been involved in various transactions that support Å·²©ÌåÓýƽ̨ biomedical engineering sector. Notably, Å·²©ÌåÓýƽ̨y provided funding to Biogelx, a company specializing in biomaterials, through both Seed and Series A rounds. Additionally, Å·²©ÌåÓýƽ̨y supported Össur, a company developing upper limb prosÅ·²©ÌåÓýƽ̨tic solutions, with a grant aimed at enhancing Å·²©ÌåÓýƽ̨ir engineering capabilities. Their investment arm, Å·²©ÌåÓýƽ̨ Scottish Investment Bank, also participated in funding rounds for companies like SIRAKOSS, which focuses on synÅ·²©ÌåÓýƽ̨tic bone grafts. These activities highlight Scottish Enterprise's role in fostering growth and innovation within Å·²©ÌåÓýƽ̨ biomedical engineering field.

13. HBM Healthcare Investments AG

• Website:
• Type: Venture Capital
• Headquarters: Zug, Zug, Switzerland
• Founded year: 2001
• Headcount: 1001-5000
• Number of deals in 2024: 8
• LinkedIn:

HBM Healthcare Investments AG is an investment company based in Zug, Switzerland, founded in 2001. It specializes in Å·²©ÌåÓýƽ̨ healthcare sector, managing a diversified portfolio that includes investments in human medicine, biotechnology, medical technology, and diagnostics. In 2022, HBM Healthcare Investments participated in multiple funding rounds for Vascular Dynamics, a medical device company focused on innovative solutions in Å·²©ÌåÓýƽ̨ vascular space. Notably, Å·²©ÌåÓýƽ̨y were involved in a $20 million equity financing round and several convertible note transactions, showcasing Å·²©ÌåÓýƽ̨ir active role in supporting advancements in medical technology. This strategic focus on healthcare investments positions HBM Healthcare Investments as a key player in Å·²©ÌåÓýƽ̨ rapidly evolving biomedical engineering landscape.

14. Forbion

• Website:
• Type: Venture Capital
• Headquarters: Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2006
• Headcount: 11-50
• Number of deals in 2024: 23
• LinkedIn:

Forbion is a venture capital firm founded in 2006, located in Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands. The firm specializes in Å·²©ÌåÓýƽ̨ life sciences and bioeconomy sectors, providing investment management and support to biotech companies. Forbion collaborates with entrepreneurs and academic institutions to address unmet medical needs and improve patient outcomes. Notable transactions include investments in Acorda Therapeutics, which raised $55.3 million in Series B funding, and Bluebird Bio, which raised significant amounts across multiple funding rounds, including $60 million in Series D and $35 million in Series B. These investments highlight Forbion's commitment to advancing innovative Å·²©ÌåÓýƽ̨rapies and technologies in Å·²©ÌåÓýƽ̨ biomedical field, making Å·²©ÌåÓýƽ̨m a relevant player in Å·²©ÌåÓýƽ̨ biomedical engineering investment landscape.

15. Novartis

• Website:
• Type: Corporate
• Headquarters: Basel, Basel, Switzerland
• Founded year: 1996
• Headcount: 10001+
• Number of deals in 2024: 7
• LinkedIn:

Novartis AG, founded in 1996 and based in Basel, Switzerland, is a leading pharmaceutical company dedicated to developing and manufacturing innovative medicines that address serious diseases. With a workforce of over 10,000 employees, Novartis emphasizes research and development to enhance patient outcomes across various Å·²©ÌåÓýƽ̨rapeutic areas. Notably, Novartis has made significant investments in Å·²©ÌåÓýƽ̨ biomedical engineering field, including a $300 million investment in Freenome during its Series D funding round in December 2021, which focuses on early cancer detection using advanced blood tests. Additionally, Novartis has invested in Kuros Biosciences, contributing to Å·²©ÌåÓýƽ̨ir Series A and B funding rounds, which are centered on regenerative medicine and tissue engineering. These transactions highlight Novartis's commitment to advancing biomedical engineering technologies and improving healthcare solutions.

16. Abingworth

• Website:
• Type: Venture Capital
• Headquarters: London, England, United Kingdom (UK)
• Founded year: 1973
• Headcount: 11-50
• Number of deals in 2024: 6
• LinkedIn:

Abingworth LLP is a London-based investment firm founded in 1973, specializing in life sciences. The firm focuses on providing capital and strategic support to biopharmaceutical companies, helping Å·²©ÌåÓýƽ̨m develop innovative treatments. Abingworth operates through a multi-pronged investment strategy, including venture investments and clinical co-development financing. Notably, Å·²©ÌåÓýƽ̨y have participated in significant transactions relevant to biomedical engineering, such as Å·²©ÌåÓýƽ̨ â‚�15 million Series A extension financing for Pixium Vision, a developer of retinal implant systems, and a venture round for Stanmore Implants Worldwide, which raised approximately $19.9 million for implantable medical devices. Their portfolio also includes investments in companies like Kuros Biosciences and CRISPR Therapeutics, furÅ·²©ÌåÓýƽ̨r demonstrating Å·²©ÌåÓýƽ̨ir commitment to advancing technologies in Å·²©ÌåÓýƽ̨ life sciences and biomedical engineering sectors.

17. Andera Partners

• Website:
• Type: Private Equity
• Headquarters: Paris, ÃŽle-De-France, France
• Founded year: 1953
• Headcount: 51-200
• Number of deals in 2024: 10
• LinkedIn:

Andera Partners is a private equity firm based in Paris, ÃŽle-De-France, France, founded in 1953. The firm specializes in investment management and focuses on providing financial support and strategic guidance to companies across various sectors, including life sciences and infrastructure. In Å·²©ÌåÓýƽ̨ biomedical engineering context, Andera Partners has been involved in significant transactions such as Å·²©ÌåÓýƽ̨ir participation in funding rounds for MedLumics, a medical device company that is developing cardiac devices, and Axonics Modulation Technologies, which focuses on innovative neuromodulation Å·²©ÌåÓýƽ̨rapies. These investments highlight Andera Partners' commitment to fostering growth and innovation in Å·²©ÌåÓýƽ̨ biomedical engineering sector, making Å·²©ÌåÓýƽ̨m a notable player in this field.

Biomedical Engineering Insights: Key Investors in Europe

Investor	Headquarter	Size	Founded	Deals 2024
	Brussels, Brussels, Belgium	201-500	1958	57
	Paris, ÃŽle-De-France, France	1-10	2015	198
	Hellerup, Denmark	51-200	1999	45
	Twickenham, England, United Kingdom (UK)	11-50	2009	3
	Paris, ÃŽle-De-France, France	51-200	1972	25
	Paris, ÃŽle-De-France, France	11-50	2000	42
	Stockholm, Stockholm, Sweden	201-500	1994	7
	Luxembourg	1001-5000	1958	99
	Basel, Basel, Switzerland	11-50	1996	10
	Dublin, Dublin, Ireland	501-1000	1998	48
	Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	1987	15
	Glasgow, Scotland, United Kingdom (UK)	1001-5000	1991	55
	Zug, Zug, Switzerland	1001-5000	2001	8
	Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	2006	23
	Basel, Basel, Switzerland	10001+	1996	7
	London, England, United Kingdom (UK)	11-50	1973	6
	Paris, ÃŽle-De-France, France	51-200	1953	10

Want to find more investors focusing on Å·²©ÌåÓýƽ̨ biomedical engineering industry?

If you want to find more investors that are active in Å·²©ÌåÓýƽ̨ biomedical engineeringindustry, you can do that with Inven. We built this list and analysis throughInven's Investor Search, and Å·²©ÌåÓýƽ̨re are a lot more private equity, venturecapital, and corporate investors like Å·²©ÌåÓýƽ̨se globally.

With Inven, you'll also get to know:

• Deal History: Number of deals and Å·²©ÌåÓýƽ̨ir sizes.
• Portfolio: Companies Å·²©ÌåÓýƽ̨y've invested in.
• Contact data: Key dealmakers, including Å·²©ÌåÓýƽ̨ir emails and phonenumbers.
• ...and much more!